Drug intelligence / Profile preview

Princess Clotho

Development stage: Preclinical
Lead developer: Saisei Mirai
Modality: Recombinant Proteins and Enzymes
Administration: Oral, Sublingual, Topical

Overview

Princess Clotho is a premium dietary supplement developed by Saisei Pharma and Saisei Mirai, designed as the global-facing brand of MAF Capsules Triple. It contains macrophage activating factor (MAF) derived from bovine whey protein using patented enzymatic technology. MAF is a degalactosylated glycoprotein (similar to GcMAF) that stimulates macrophage activation and mucosal immunity in the gut. Princess Clotho is marketed for anti-aging, longevity, and immune support, with research suggesting it may support telomere elongation and promote the expression of the longevity-associated gene α-Klotho.

Brand names: MAF Capsules TripleMAF TriplePrincess Clotho
Other names: Dietary MAFdegalactosylated vitamin D-binding proteinwhey-derived macrophage activating factor

Beyond the preview

Go deeper on Princess Clotho.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Princess Clotho.